ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Biosero Appoints Rob Harkness as Chief Technology Officer

Biosero, Inc., developer of laboratory automation solutions to orchestrate scientific discoveries, today announced the promotion of Rob Harkness, PhD, to the position of Chief Technology Officer. Dr. Harkness previously served as the company’s managing director for the European Union and United Kingdom.

“In the three years Rob has been at Biosero, he has consistently impressed me with his technical competencies, future vision, and commitment to ensuring customer success,” said Tom Gilman, President and CEO at Biosero. “Rob has an extensive background in laboratory automation and a keen sense of what customers need to accelerate their science. I can’t imagine a better fit to be our next CTO as Biosero continues to push the boundaries of what’s possible in lab automation and orchestration.”

Dr. Harkness has more than 20 years of experience in delivering laboratory automation solutions. He joined Biosero in 2020, initially as director of customer success for the EU and UK, working with customers and partners to help them achieve their scientific goals. He has also been instrumental in the development of the company’s business strategy and technology roadmap.

Prior to Biosero, Dr. Harkness held roles of increasing responsibility at automation and robotics companies such as CyBio, Astech Projects, and Peak Analysis and Automation. Dr. Harkness also serves as a director for the Standards in Laboratory Automation (SiLA) consortium, an initiative in the life science community to create open system communication and data standards to promote the utility and accessibility of lab automation. He earned his bachelor of science in computer-aided chemistry and his PhD in biochemical assay automation software, both from the University of Surrey.

“Biosero’s commitment to customers — measuring our success not by installations or units sold but by the automation-powered achievements of the researchers we serve — has resonated with me since day one,” said Dr. Harkness. “I am honored to take on this new role and look forward to guiding Biosero’s technology strategy as we seek to empower customers and laboratories around the world with our software and automation solutions.”

Biosero’s outgoing CTO, David Dambman, will continue to consult with the company on automation and technology projects. “I am deeply grateful to David for giving so much of himself to Biosero and our customers for the past 13 years,” said Mr. Gilman. “He transformed both our and the industry’s overall approach to laboratory automation with his development of Green Button Go software and I’m thrilled that we will have the opportunity to continue working together even as he moves to his next chapter.”

About Biosero, Inc.

Biosero, a member of the BICO group, develops science-centric software and laboratory automation solutions that enable researchers to orchestrate their discoveries at every stage. Biosero’s Green Button Go® Scheduler software and integration services match laboratory automation to science, creating a cohesive technology ecosystem that accelerates operations and increases productivity. Additionally, Green Button Go Orchestrator applications provide an end-to-end laboratory management solution, directing workflows and operations in life science, biotechnology, pharmaceutical, and diagnostic research. Biosero is passionate about partnering with organizations dedicated to enhancing life by addressing the world’s most significant needs. For more information, please visit www.biosero.com.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.